Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Microbot Medical Inc. (NASDAQ: MBOT), a commercial stage medical device company focused on the LIBERTY Endovascular Robotic System. Through these filings, investors can review how the company reports material events, financing transactions, intellectual property developments and key commercialization steps for its endovascular robotics platform.
Microbot Medical uses current reports on Form 8-K to disclose significant milestones, including FDA 510(k) clearance for the LIBERTY System, the start of its limited market release in the U.S., and the first hospital adoption of LIBERTY for patient care at Emory University Hospital. Other 8-K filings describe partnerships with a U.S.-based third-party logistics provider to support commercialization, as well as the company’s exhibition of LIBERTY at major medical meetings.
Several 8-K filings also detail capital markets activity, such as the exercise of outstanding preferred investment options, issuance of new short-term preferred investment options and related gross proceeds. In these documents, Microbot Medical outlines intended uses of funds, including continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion of applications derived from its IP portfolio, and working capital and general corporate purposes.
Additional filings address intellectual property events, such as the granting of the company’s first patent in Japan covering core LIBERTY System technology, and certain compensation decisions for executives and non-management directors. On Stock Titan, these filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the context and key points of each document, from material event disclosures to financing terms and governance changes related to MBOT.
Microbot Medical Inc. filed a report describing a press release about its LIBERTY® Endovascular Robotic System being highlighted at the International Symposium on Endovascular Therapy conference in Miami Beach, Florida.
The company notes that LIBERTY, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, was prominently discussed in a town hall session on advances in endovascular robotics. Management states that LIBERTY is in a limited market release that began in late 2025 and that a full market release is planned at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a report stating that it is attending the Society of Interventional Oncology annual meeting in Savannah, Georgia, held February 4–8, 2026. The timing coincides with the company’s limited market release of its LIBERTY Endovascular Robotic System.
During the meeting, Microbot plans to share practical insights and personal experiences from physicians who have used LIBERTY across different hospitals and procedure types. The company furnished, but did not file, a related press release as Exhibit 99.1 under Regulation FD.
Microbot Medical Inc. investors report an 8.2% beneficial stake in the company’s common stock. The filing is a Schedule 13G submitted jointly by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on January 23, 2026, they report beneficial ownership of 6,002,185 shares of common stock, all issuable upon exercise of a warrant held by Intracoastal. This stake is calculated as approximately 8.2% of the common stock, based on 67,158,044 shares outstanding as of November 14, 2025 plus the warrant shares. The reporting persons have shared, but not sole, voting and dispositive power over these shares and certify they do not hold the securities for the purpose of changing or influencing control of the issuer.
Microbot Medical Inc. filed a current report to share that it issued a press release on January 12, 2026. The release reaffirms the company’s achievements in 2025 and announces key anticipated milestones for 2026, highlighting its recent progress and future business, regulatory, or financial targets. The press release is furnished as Exhibit 99.1 and incorporated by reference, and the company includes customary cautionary language that statements about expected future milestones are forward-looking and subject to various risks and uncertainties.
Microbot Medical Inc. reported that Emory University Hospital in Atlanta has become the first hospital in the world to adopt its LIBERTY® Endovascular Robotic System for patient care. This marks the system’s transition from development and evaluation into real-world clinical use at a major academic medical center.
The company is also collaborating with Emory to establish an Endovascular Robotics Program within interventional radiology. This collaboration is intended to integrate robotic technology into clinical workflows and may help build clinical experience and visibility for the LIBERTY system over time.
Microbot Medical Inc. is registering up to 14,688,572 shares of common stock for resale by existing selling stockholders, issuable upon exercise of outstanding preferred investment options. The company itself is not selling shares in this offering and will not receive proceeds from any resale, although it may receive up to approximately $64.8 million in gross proceeds if all 14,688,572 options are exercised for cash, which would be used for working capital. Shares outstanding were 67,158,044 as of November 14, 2025. Microbot highlights recent progress for its LIBERTY® Endovascular Robotic Surgical System, including U.S. FDA 510(k) clearance in September 2025 and ISO 13485:2016 certification, and notes plans to pursue CE Mark approval in the second half of 2026. The company also discusses new patents in Japan, China and the U.S., and outlines risks related to ongoing regional military conflicts affecting its Israel-based operations.
Microbot Medical Inc. is registering up to 900,153 shares of common stock for resale by certain selling stockholders, consisting of shares issuable upon exercise of outstanding preferred investment options. The company is not selling any shares in this offering and will not receive proceeds from stockholder resales, though it may receive up to approximately $2.1 million in gross proceeds if all 900,153 options are exercised for cash.
Microbot is a medical device company developing next-generation robotic systems for minimally invasive endovascular procedures, led by its LIBERTY® Endovascular Robotic Surgical System. On September 8, 2025, LIBERTY received FDA 510(k) clearance for peripheral endovascular procedures, and a limited U.S. market release began on November 5, 2025, with a broader launch anticipated in April 2026. The company reports recent patents in Japan, the United States, and China, ISO 13485:2016 certification supporting a CE Mark it anticipates in the second half of 2026, and collaboration with Emory University on autonomous robotics. It also discusses risks from ongoing military conflict affecting its Israel-based operations, noting no material adverse effects as of the prospectus date but no specific contingency plans.
Microbot Medical (MBOT) reported Q3 2025 results, highlighting a larger cash position to support commercialization preparation and ongoing R&D. Cash and cash equivalents were $6.7 million with marketable securities of $73.5 million, bringing total current assets to $80.8 million as of September 30, 2025. The company recorded a net loss of $3.6 million (basic and diluted loss per share of $0.07) for the quarter.
Shareholders’ equity rose to $78.2 million, aided by equity financings and warrant exercises during the year. Shares outstanding were 65,833,556 as of September 30, 2025; the company later reported 67,158,044 shares as of November 12, 2025. Management noted funds are sufficient to operate for more than twelve months from the financial statement issuance date.
Operationally, the FDA granted 510(k) clearance for the LIBERTY Endovascular Robotic Surgical System, and the company increased authorized common shares to 120,000,000 in June 2025 to support capital needs. Marketable securities expanded as proceeds were invested in money market mutual funds.
Microbot Medical (MBOT) announced U.S. commercial availability of its LIBERTY Endovascular Robotic System on a limited basis. The company is initiating a limited market release to selected high procedure volume regions where it has already experienced preliminary demand.
The update was shared via a press release furnished under Regulation FD and listed as Exhibit 99.1. This marks an initial commercialization step intended to introduce LIBERTY to targeted centers in the United States.
Microbot Medical Inc. filed Amendment No. 1 to its Form S-3 registration statement. The amendment adds Rule 473(b) language for automatic effectiveness 20 days following filing and updates a cross-reference in the exhibit index. It does not modify any provision of the prospectus, and a preliminary prospectus has been omitted.
The filing states effectiveness will occur in accordance with Section 8(a) of the Securities Act. Listed issuance and distribution expenses total $25,000.00, including an SEC registration fee of $404.02, with legal, accounting, and miscellaneous costs itemized.